中文摘要：

目的观察黄芪消白颗粒治疗慢性肾小球肾炎蛋白尿的疗效及安全性。方法采用完全随机对照方法，将2012年8月至2014年12月上海中医药大学附属曙光医院肾病科门诊慢性肾小球肾炎患者52例按就诊顺序编号随机分为2组。对照组常规治疗，肾病饮食，控制血压130-90／80-60mm Hg之间，给予苯那普利10mg／次，每天1次口服；治疗组给予黄芪消白颗粒（14g／包，1包／次）每天3次口服，连续治疗随访24周。观测24h尿蛋白定量、肾小球滤过率（estimated glomerular filtration rate，eGFR）、血红蛋白、血白蛋白、丙氨酸氨基转移酶、血钾等疗效及安全性指标，监测不良反应。结果观察24周，治疗组临床缓解2例，显效12例，有效5例，无效8例，总有效率70．37％。对照组临床缓解1例，显效3例，有效6例，无效15例，总有效率40．00％。治疗组疗效优于对照组（〈d0．05）。2组24h尿蛋白定量的变化率比较，差异有统计学意义（P〈0．05），eGFR的变化率无统计学差异（P〉0．05）。黄芪消白颗粒治疗前后血红蛋白、血白蛋白、血钾等方面无统计学差异（P〉0．05），治疗后丙氨酸氨基转移酶较治疗前改善，差异有统计学意义（P〈O．05）。本研究中共发生不良反应7例，与实验方案没有关系，没有因为不良事件而退出研究。结论黄芪消白颗粒能够改善气虚湿淤型慢性肾小球肾炎蛋白尿，稳定肾功能，疗效确切，且没有明显的不良反应，具有很好的安全性。

英文摘要：

Objective To observe the efficacy and safety of Huangqixiaobai particles in treating chro- nic glomerulonephritis. Methods With completely random control method, 52 cases from Shuguang Hospital Nephrology outpatients between August 2012 to December 2014, are divided into two groups. One is control group, the other is treatment group. All the patients accept the conventional treatment, with the kidney diet, with the blood pressure controled between 130 - 90/80 - 60 mm Hg. The control group take benazepril, 10 mg/times, 1 times/day, orally. The treatment group take Huangqixiaobai particles, 1 pack- et/time, 3 times/day, orally. Follow-up of 24 weeks of continuous treatment. Observation 24 hours urinary protein, eGFR, hemoglobin, serum albumin, serum potassium, and adverse reactions. Results In the treatment group, 2 cases are clinical remission, 12 cases are markedly effective, .5 cases are effective, and 8 eases are ineffective. The total efficiency is 70. 37%. In the control group, 1 cases are clinical remission, 3 cases are markedly effective, 6 cases are effective, and 15 cases are ineffective. The total efficiency is 40. 00%. The efficacy of treatment group is better than the control group（P〈0. 05）. The rate of change in 24-hour u-rinary protein excretion between the two groups is significantly different（P〈0. 05）, no statistically significant difference in the rate of change in eGFR. There is no statistically significant difference between before and after the treetment of Huangqixiaobai particles in hemoglobin, serum albumin, serum potassium and so on（P〉0. 05）. After treatment of Huangqixiaobai particles, alanine aminotransferase is improved, showing statistical significance. There are totally seven eases of adverse events during study process, all are adverse reactions. All the adverse events are not related to the experimental program. No patient withdrawn from the study because of adverse events. Conelusions Huangqixiaobai particles can improve the urinary protein of chronic glomemlonephr